CBA 1205
Alternative Names: CBA 1205; LIV-1205Latest Information Update: 28 Feb 2025
At a glance
- Originator Chiome Bioscience; LivTech
- Developer ADC Therapeutics; Chiome Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Mitogen-activated protein kinase kinase kinase 12 modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Liver cancer
Most Recent Events
- 21 Jan 2025 Efficacy, Pharmacokinetic and adverse events data from a phase I trial in solid tumours released by Chiome Bioscience
- 20 Dec 2024 Efficacy and adverse events data from a phase I trial in solid tumours released by Chiome Bioscience
- 28 Aug 2023 Phase I development in solid tumour is ongoing in Japan (Chiome Bioscience pipeline, August 2023)